Cagrilintide is an amylin analog studied for its association with weight-management and metabolic wellness pathways. It is commonly explored in provider-directed weight-management programs and should be evaluated based on the individual patient, treatment objective, and applicable prescribing information.
What It Is Used For
Cagrilintide is commonly considered in provider-directed programs focused on the following areas of interest:
Weight Management — Often considered in provider-directed programs focused on weight management and body-composition wellness goals.
Metabolic Health — May be explored within programs designed to support metabolic regulation and related wellness objectives.
Appetite Regulation Support — May be considered for patients whose goals include appetite regulation and satiety-related wellness support.
Cagrilintide should be evaluated against applicable prescribing information. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.
How It Works
Cagrilintide is a synthetic analog of amylin, a peptide co-secreted with insulin from pancreatic beta cells, studied for its association with weight-management and metabolic pathways. Areas of biological activity include:
Areas being studied include:
Amylin Receptor Interaction — Cagrilintide has been studied for its interaction with amylin receptors, which are involved in appetite regulation and satiety signaling.
Appetite and Satiety Signaling — Research has investigated potential effects on central appetite-regulation and satiety-related signaling pathways.
Gastric Emptying — Preclinical research has explored potential effects on gastric emptying and related metabolic processes.
Metabolic and Weight-Management Pathways — Research has explored potential effects on metabolic pathways associated with weight management.
Clinical use of Cagrilintide varies by patient-specific factors and applicable prescribing information. The treating healthcare professional remains responsible for all clinical decision-making. This information is educational and does not establish clinical efficacy for any specific use.
Clinical Information
Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering Cagrilintide for a patient.
Include these considerations:
Patient-Specific Assessment Required — Providers should consider the patient's medical history, current medications, allergies, pregnancy or breastfeeding status, and other relevant clinical factors before use.
Use Within Approved and Appropriate Context — Cagrilintide should be evaluated against applicable prescribing information and used only where clinically appropriate for the individual patient.
Monitor Tolerance and Relevant Clinical Factors — Providers should monitor patient tolerance and relevant clinical factors, including appetite-related and metabolic factors, throughout the course of use.
Treatment Decisions Remain With the Licensed Healthcare Professional — All treatment, prescribing, and dosing decisions remain solely the responsibility of the appropriately licensed healthcare professional.
ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.
Available Options
Option 1
Verified formulations and strengths will be updated based on current pharmacy availability.
Dosing & Reconstitution
For provider use only. Calculates reconstitution math — does not select or recommend a patient dose.
Product Dosing Schedule
Provider Inputs
Calculated Outputs
Concentration
—
Medication amount ÷ diluent mL
Volume to Draw
—
Desired dose ÷ concentration
U-100 Syringe Units
—
Volume to draw × 100 — 100 syringe units = 1.00 mL · 1 syringe unit = 0.01 mL
| Weeks 1–4 — 0.25 mg | once weekly |
| Weeks 5–8 — 0.50 mg | once weekly |
| Weeks 9–12 — 1 mg | once weekly |
| Weeks 13–16 — 1.7 mg | once weekly |
| Week 17+ — 2.4 mg | once weekly |
Titration schedule. Follow the verified escalation steps; the maximum/reference maintenance value is the final step.
Dosing information is provided for healthcare-professional reference only when verified. Patient-specific dosing and prescribing decisions remain the responsibility of the treating healthcare professional.
This tool performs reconstitution/administration math only. It does not select, recommend, or validate a patient dose. Dosing decisions are the responsibility of the prescribing healthcare provider.
Ask ALML
Ask ALML may identify Cagrilintide as a product for a healthcare professional to explore when the described patient goals involve weight management, appetite regulation, or metabolic health.
The match is informational. Ask ALML is designed to help healthcare professionals navigate the ALML portfolio and identify potentially relevant options for further clinical consideration. It does not diagnose a patient, prescribe treatment, determine medical necessity, or select patient-specific dosing.
Submit an order request or ask about availability. A request is not a guaranteed order — every inquiry goes to ALML staff for manual review and follow-up.
ALML does not guarantee that any specific therapy can be supplied. Availability is confirmed through manual review of each request.